BRPI0911350A2 - conjugado de polietileno glicol, método para tratar hemofilia b, e, método para reduzir o risco de doenças ou condições. - Google Patents
conjugado de polietileno glicol, método para tratar hemofilia b, e, método para reduzir o risco de doenças ou condições.Info
- Publication number
- BRPI0911350A2 BRPI0911350A2 BRPI0911350A BRPI0911350A BRPI0911350A2 BR PI0911350 A2 BRPI0911350 A2 BR PI0911350A2 BR PI0911350 A BRPI0911350 A BR PI0911350A BR PI0911350 A BRPI0911350 A BR PI0911350A BR PI0911350 A2 BRPI0911350 A2 BR PI0911350A2
- Authority
- BR
- Brazil
- Prior art keywords
- disease
- risk
- reducing
- conditions
- polyethylene glycol
- Prior art date
Links
- 208000031220 Hemophilia Diseases 0.000 title 1
- 208000009292 Hemophilia A Diseases 0.000 title 1
- 239000002202 Polyethylene glycol Substances 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 229920001223 polyethylene glycol Polymers 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/644—Coagulation factor IXa (3.4.21.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21022—Coagulation factor IXa (3.4.21.22)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4754408P | 2008-04-24 | 2008-04-24 | |
PCT/IB2009/005763 WO2009130602A2 (en) | 2008-04-24 | 2009-04-24 | Factor ix conjugates with extended half-lives |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0911350A2 true BRPI0911350A2 (pt) | 2017-12-05 |
Family
ID=41171051
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0911350A BRPI0911350A2 (pt) | 2008-04-24 | 2009-04-24 | conjugado de polietileno glicol, método para tratar hemofilia b, e, método para reduzir o risco de doenças ou condições. |
Country Status (23)
Country | Link |
---|---|
US (1) | US20110183906A1 (pt) |
EP (1) | EP2280734B1 (pt) |
JP (1) | JP2011519833A (pt) |
KR (1) | KR20110016440A (pt) |
CN (1) | CN102046205A (pt) |
AU (1) | AU2009239641B2 (pt) |
BR (1) | BRPI0911350A2 (pt) |
CA (1) | CA2722169A1 (pt) |
CO (1) | CO6300965A2 (pt) |
CR (1) | CR11763A (pt) |
DK (1) | DK2280734T3 (pt) |
EC (1) | ECSP10010632A (pt) |
ES (1) | ES2466340T3 (pt) |
HK (1) | HK1151986A1 (pt) |
IL (1) | IL208908A0 (pt) |
MX (1) | MX2010011672A (pt) |
MY (1) | MY158228A (pt) |
NI (1) | NI201000177A (pt) |
NZ (1) | NZ588854A (pt) |
RU (1) | RU2496521C2 (pt) |
UA (1) | UA101497C2 (pt) |
WO (1) | WO2009130602A2 (pt) |
ZA (1) | ZA201007559B (pt) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5876208B2 (ja) | 2006-12-15 | 2016-03-02 | バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated | 延長されたinvivo半減期を有する第VIIa因子−(ポリ)シアル酸結合体 |
US8809501B2 (en) | 2009-07-27 | 2014-08-19 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
JP5909755B2 (ja) | 2009-07-27 | 2016-04-27 | リポクセン テクノロジーズ リミテッド | 非血液凝固タンパク質の糖ポリシアル酸化 |
HUE028056T2 (en) | 2009-07-27 | 2016-11-28 | Baxalta GmbH | Blood coagulation protein conjugates |
US8642737B2 (en) | 2010-07-26 | 2014-02-04 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
JP5908401B2 (ja) | 2009-07-27 | 2016-04-26 | バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated | 血液凝固タンパク質複合体 |
CN102470182A (zh) * | 2009-08-20 | 2012-05-23 | 德国杰特贝林生物制品有限公司 | 用于在出血性紊乱的治疗和预防性处理中进行非静脉内施用的白蛋白融合凝血因子 |
GB201007356D0 (en) * | 2010-04-30 | 2010-06-16 | Leverton Licence Holdings Ltd | Conjugated factor VIIa |
GB201007357D0 (en) * | 2010-04-30 | 2010-06-16 | Leverton Licence Holdings Ltd | Conjugated factor VIII |
EP3552619A1 (en) * | 2010-07-09 | 2019-10-16 | Bioverativ Therapeutics Inc. | Factor ix polypeptides and methods of use thereof |
EP2654794B8 (en) | 2010-12-22 | 2020-04-22 | Baxalta GmbH | Materials and methods for conjugating a water soluble fatty acid derivative to a protein |
CA2836478A1 (en) * | 2011-05-27 | 2012-12-06 | Baxter International Inc. | Therapeutic protein conjugated to water-soluble polymers via reduced cysteine sulfhydryl group |
EA033469B1 (ru) | 2012-04-16 | 2019-10-31 | Cantab Biopharmaceuticals Patents Ltd | Подкожное введение конъюгатов факторов крови с полиэтиленгликолем |
AU2013279099A1 (en) * | 2012-06-19 | 2014-12-18 | Polytherics Limited | Novel process for preparation of antibody conjugates and novel antibody conjugates |
EP3542861A1 (en) | 2012-09-25 | 2019-09-25 | Bioverativ Therapeutics Inc. | Methods of using fix polypeptides |
SG11201505926VA (en) | 2013-03-15 | 2015-09-29 | Biogen Ma Inc | Factor ix polypeptide formulations |
AR099340A1 (es) * | 2014-02-12 | 2016-07-13 | Novo Nordisk As | Conjugados del factor de coagulación ix |
GB2564389A (en) | 2017-07-04 | 2019-01-16 | Green Running Ltd | A system and method for utility management |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5171569A (en) | 1985-03-15 | 1992-12-15 | National Research Development Corporation | Factor IX preparations uncontaminated by plasma components or pox virus |
US5268275A (en) | 1991-05-08 | 1993-12-07 | The University Of North Carolina At Chapel Hill | Vitamin K-dependent carboxylase |
US5621039A (en) * | 1993-06-08 | 1997-04-15 | Hallahan; Terrence W. | Factor IX- polymeric conjugates |
US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
WO1999003496A1 (en) | 1997-07-21 | 1999-01-28 | The University Of North Carolina At Chapel Hill | Factor ix antihemophilic factor with increased clotting activity |
WO2000054787A1 (en) | 1999-03-16 | 2000-09-21 | The Children's Hospital Of Philadelphia | Enhanced gamma-carboxylation of recombinant vitamin k-dependent clotting factors |
PL204285B1 (pl) * | 2000-02-11 | 2009-12-31 | Bayer Healthcare Llc | Koniugat polipeptydowy, polipeptyd, sekwencja nukleotydowa, wektor ekspresyjny, komórka gospodarz, sposób wytwarzania koniugatu polipeptydowego, środek farmaceutyczny i zastosowanie koniugatu polipeptydowego |
AU2003300139B2 (en) * | 2002-12-31 | 2008-08-28 | Nektar Therapeutics | Maleamic acid polymer derivatives and their bioconjugates |
KR101025143B1 (ko) * | 2002-12-31 | 2011-04-01 | 넥타르 테라퓨틱스 | 가수분해상으로 안정한 말레이미드-종결 중합체 |
DE602004029646D1 (en) * | 2003-01-06 | 2010-12-02 | Nektar Therapeutics San Carlos | Thiolselektive wasserlösliche polymerderivate |
GB0316294D0 (en) * | 2003-07-11 | 2003-08-13 | Polytherics Ltd | Conjugated biological molecules and their preparation |
WO2005030039A2 (en) | 2003-09-23 | 2005-04-07 | University Of North Carolina At Chapel Hill | Methods and compositions for the correlation of single nucleotide polymorphisms in the vitamin k epoxide reductase gene and warfarin dosage |
WO2005033140A1 (ja) * | 2003-09-30 | 2005-04-14 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | 高純度血液凝固ix因子調製物およびその精製方法 |
DE602004026897D1 (de) | 2003-10-14 | 2010-06-10 | Baxter Healthcare Sa | Vkorc1 (vitamin k epoxide recycling polypeptide), ein therapeutisches ziel für coumarin und deren derivate |
US20060040856A1 (en) * | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
US7579444B2 (en) * | 2004-06-30 | 2009-08-25 | Nektar Therapeutics Al, Corporation | Polymer-factor IX moiety conjugates |
EP1819829A1 (en) | 2004-12-08 | 2007-08-22 | ICOS Corporation | Recombinant method for making multimeric proteins |
MX2007010489A (es) | 2005-02-28 | 2007-11-08 | Baxter Int | Co-expresion recombinante de reductasa de epoxido de vitamina k subunidad 1 para mejorar la expresion de proteina dependiente de vitamina k. |
JP2008532544A (ja) | 2005-03-15 | 2008-08-21 | ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | 活性ビタミンk依存性タンパク質を生産するための方法及び組成物 |
EP2975135A1 (en) * | 2005-05-25 | 2016-01-20 | Novo Nordisk A/S | Glycopegylated factor IX |
AU2007245190B2 (en) * | 2006-03-31 | 2011-07-21 | Takeda Pharmaceutical Company Limited | Pegylated factor VIII |
RU2008145084A (ru) * | 2006-05-24 | 2010-06-27 | Ново Нордиск Хелс Кеа Аг (Ch) | Аналоги фактора ix, имеющие пролонгированное время полужизни in vivo |
JP5737821B2 (ja) * | 2006-08-17 | 2015-06-17 | 一夫 大橋 | 血友病b治療剤及びその製造方法 |
-
2009
- 2009-04-24 MY MYPI2010004993A patent/MY158228A/en unknown
- 2009-04-24 CA CA2722169A patent/CA2722169A1/en not_active Abandoned
- 2009-04-24 WO PCT/IB2009/005763 patent/WO2009130602A2/en active Application Filing
- 2009-04-24 DK DK09734192.9T patent/DK2280734T3/da active
- 2009-04-24 CN CN200980119877XA patent/CN102046205A/zh active Pending
- 2009-04-24 UA UAA201013989A patent/UA101497C2/ru unknown
- 2009-04-24 MX MX2010011672A patent/MX2010011672A/es active IP Right Grant
- 2009-04-24 KR KR1020107026368A patent/KR20110016440A/ko not_active Application Discontinuation
- 2009-04-24 EP EP09734192.9A patent/EP2280734B1/en not_active Not-in-force
- 2009-04-24 RU RU2010147813/15A patent/RU2496521C2/ru not_active IP Right Cessation
- 2009-04-24 US US12/989,555 patent/US20110183906A1/en not_active Abandoned
- 2009-04-24 AU AU2009239641A patent/AU2009239641B2/en not_active Ceased
- 2009-04-24 BR BRPI0911350A patent/BRPI0911350A2/pt not_active IP Right Cessation
- 2009-04-24 ES ES09734192.9T patent/ES2466340T3/es active Active
- 2009-04-24 NZ NZ588854A patent/NZ588854A/en not_active IP Right Cessation
- 2009-04-24 JP JP2011505616A patent/JP2011519833A/ja active Pending
-
2010
- 2010-10-22 ZA ZA2010/07559A patent/ZA201007559B/en unknown
- 2010-10-22 NI NI201000177A patent/NI201000177A/es unknown
- 2010-10-24 IL IL208908A patent/IL208908A0/en unknown
- 2010-10-27 CR CR11763A patent/CR11763A/es not_active Application Discontinuation
- 2010-11-24 CO CO10147494A patent/CO6300965A2/es not_active Application Discontinuation
- 2010-11-24 EC EC2010010632A patent/ECSP10010632A/es unknown
-
2011
- 2011-06-15 HK HK11106190.2A patent/HK1151986A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
ES2466340T3 (es) | 2014-06-10 |
RU2010147813A (ru) | 2012-05-27 |
CO6300965A2 (es) | 2011-07-21 |
UA101497C2 (ru) | 2013-04-10 |
MY158228A (en) | 2016-09-15 |
MX2010011672A (es) | 2011-03-02 |
HK1151986A1 (en) | 2012-02-17 |
WO2009130602A3 (en) | 2010-02-11 |
EP2280734B1 (en) | 2014-02-26 |
US20110183906A1 (en) | 2011-07-28 |
CN102046205A (zh) | 2011-05-04 |
CR11763A (es) | 2011-04-26 |
IL208908A0 (en) | 2011-01-31 |
AU2009239641B2 (en) | 2013-11-07 |
DK2280734T3 (da) | 2014-05-26 |
NI201000177A (es) | 2011-08-29 |
ECSP10010632A (es) | 2011-02-28 |
NZ588854A (en) | 2011-12-22 |
RU2496521C2 (ru) | 2013-10-27 |
ZA201007559B (en) | 2012-01-25 |
JP2011519833A (ja) | 2011-07-14 |
WO2009130602A9 (en) | 2010-04-22 |
WO2009130602A2 (en) | 2009-10-29 |
KR20110016440A (ko) | 2011-02-17 |
EP2280734A2 (en) | 2011-02-09 |
AU2009239641A1 (en) | 2009-10-29 |
CA2722169A1 (en) | 2009-10-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0911350A2 (pt) | conjugado de polietileno glicol, método para tratar hemofilia b, e, método para reduzir o risco de doenças ou condições. | |
BRPI0819842A2 (pt) | Sistema de carga e método para operar o mesmo. | |
BR112012018947A8 (pt) | composição farmacêutica para o tratamento e/ou prevenção de um câncer, anticorpo, combinação farmacêutica e método para o tratamento e/ou prevenção de um câncer | |
BR112012018951A2 (pt) | composição farmacêutica, combinação farmacêutica e método para o tratamento e\ou prevenção de um câncer e anticorpo | |
BRPI0815057A2 (pt) | Composto, composição farmacêutica, e, método para tratar infecção. | |
BRPI1011760A2 (pt) | método para prevenir ou reduzir coagulação no trato gastrointestinal superior de um indivíduo, e, uso de proteína anticoagulante. | |
BRPI0922122A2 (pt) | composições e métodos para tratamento de doença celíaca. | |
BRPI0813757A2 (pt) | Sistema de implante, e, método | |
BRPI0820843A2 (pt) | Sistema de monitoração de eletrocardiograma, e, método para operar o mesmo | |
BRPI0716439A2 (pt) | formulaÇÕes de flibanserina e mÉtodo para fabricaÇço das mesmas. | |
BRPI0920443A2 (pt) | compostos de piperazina, agente, e, processo para combater vegetacao indesejavel. | |
BRPI0717219A2 (pt) | "composição imunogênica, método para tratar ou prevenir doença, e, uso de uma composição imunogênica." | |
BRPI1006145A2 (pt) | "composição e método para tratamento de diabetes". | |
BRPI0911757A2 (pt) | composiÇÕes e mÉtodos para tratar distérbios digestivos. | |
BRPI0822633A2 (pt) | Desinfetante, e, método de esterilização. | |
BRPI0718688A2 (pt) | Composições de baixa irritação e métodos para preparar as mesmas. | |
BRPI1016158A2 (pt) | "sistema e método para monitorar um desempenho atlético, e, sistema e método de monitoramento do desempenho atlético." | |
BRPI0822756A2 (pt) | sistema de prótese de válvula cardíaca e processo para produzir prótese de válvula cardíaca. | |
BRPI0823030A2 (pt) | Sistema de elevador, e, método para fazer um sistema de elevador. | |
BRPI0813914A2 (pt) | Sistema, e, método. | |
BRPI0822078A2 (pt) | Método, e, sistema. | |
BR112012004333A2 (pt) | composto, composição farmacêutica, e, método para o tratamento ou a prevenção de uma doença ou um distúrbio. | |
BRPI0916593A2 (pt) | processo para modificação contínua de gesso diidratado e gesso diidratado modificado obtido através do processo. | |
BRPI1013396A2 (pt) | composto, produto farmacêutico de combinação, uso de um composto, método para tratar uma doença ou condição, e, processo para a preparação de um composto. | |
BRPI0816175A2 (pt) | Composições adequadas para tratamento de doença, distúrbio ou condição da espinha. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B15K | Others concerning applications: alteration of classification |
Ipc: A61K 47/00 (2006.01), C12N 9/64 (2006.01), A61P 7/ |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2450 DE 19-12-2017 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
B25B | Requested transfer of rights rejected |
Owner name: CELTIC PHARMA PEG LTD. (BM) |